Life expectancy in ovarian cancer: why early diagnosis changes everything
Ovarian cancer is one of the most complex oncological conditions in gynaecology, not only because of its biology but because of how it usually presents. Unlike other tumours, its early evolution is silent, which directly conditions life expectancy. In this article, Dr. Juan José Torrent, founder of the Quenet Torrent Institute, reviews the figures we manage today, the factors that genuinely change the prognosis and why the centre where the disease is treated weighs as heavily as the moment of diagnosis.
Today we know that talking about survival in ovarian cancer is not talking about a single figure: it is talking about a clinical situation that changes a great deal depending on the moment of diagnosis.
The impact of stage on survival
When the ovarian tumour is detected in a localised stage, confined to the ovary, five-year survival exceeds 90-95%. This places early-stage ovarian cancer among the tumours with the best prognosis in gynaecological oncology.
However, this is not the most common scenario. In clinical practice, a large proportion of patients are diagnosed when the disease has already spread through the abdominal cavity or beyond, forming a peritoneal carcinomatosis of ovarian origin. In these cases, corresponding to stages III and IV, five-year survival drops to roughly 20-40%.
That is why early diagnosis remains the main problem with this tumour.
A tumour that is hard to detect in time
Ovarian cancer rarely produces specific symptoms in its early stages. Sensations such as abdominal bloating, digestive changes or pelvic discomfort can appear subtly and be mistaken for benign processes. This lack of clear signals, combined with the absence of effective screening programmes for the general population, contributes to delayed diagnosis.
From a clinical perspective, this calls for a more proactive approach in patients with risk factors or above certain ages, where gynaecological follow-up matters more. We expand on this in our guide on how to detect ovarian cancer and its diagnostic tests.
The importance of treatment in specialised centres
Treatment in highly specialised centres directly influences survival. The accumulated experience in complex oncological surgery and in multidisciplinary decision-making matters more than the technology.
The quality of the initial surgery, especially the ability to achieve complete tumour resection through open surgery or, where appropriate, robotic surgery, is one of the most relevant prognostic factors. Add to this the development of targeted therapies and new lines of treatment, alongside the integration of molecular analysis, which allows the strategy to be tailored to the biological characteristics of the tumour.
At the Quenet Torrent Institute we bring together in a single team oncological surgery, medical oncology, molecular diagnostics and HIPEC (hyperthermic intraperitoneal chemotherapy), which is indicated in selected cases with peritoneal dissemination of ovarian origin.
Dr. Juan José Torrent
Founder & Oncological Surgeon
Quenet Torrent Institute
"Early-stage ovarian cancer has a survival rate above 90%, but outcomes decline sharply in advanced disease."
American Cancer Society
"The prognosis of ovarian cancer does not depend solely on stage, but on how it is approached from the very first moment. The combination of expert surgery, molecular diagnosis and a personalised strategy is what truly changes the patient's evolution."
Oncology Team, Quenet Torrent Institute
Beyond the figures: personalised medicine
Although stage is the single most decisive factor, it is not the only one. Tumour biology, response to treatment and the patient's genetic profile (including BRCA1/BRCA2 mutations) also influence the course of the disease. The quality of surgery is the only prognostic factor we can directly influence: a high-quality surgery, combined when indicated with HIPEC, targeted therapies and the regimens we evaluate in our clinical research line.
That is why the life expectancy of an individual patient depends a great deal on the treatment strategy followed in her case.
When the disease affects the peritoneum, we are speaking of peritoneal carcinomatosis of ovarian origin, where the combination of complete cytoreductive surgery plus HIPEC has reshaped survival curves compared with systemic chemotherapy alone.
Conclusion
What weighs most on the prognosis is early diagnosis and surgery by an experienced team, within specialised treatment from the outset.
If you need a second opinion on a diagnosis or treatment plan, the Quenet Torrent Institute team is available to evaluate your case and propose a treatment plan.
Frequently asked questions
The most common questions answered with concrete data.
What is the life expectancy in ovarian cancer?
Life expectancy varies greatly depending on the stage at diagnosis. In early stages it can exceed 90-95% at five years, while in advanced stages it drops to roughly 20-40%. Stage III is the most common at diagnosis.
Why does early diagnosis matter so much in ovarian cancer?
Because it directly determines the prognosis. When the cancer is detected confined to the ovary, 5-year survival exceeds 90%. By contrast, when it is diagnosed at advanced stages the disease has already spread through the abdominal cavity and is much harder to treat.
Can ovarian cancer be cured?
Yes, particularly in early stages, where treatment can be curative in many cases. In advanced stages, although roughly 20% of patients can be cured, the goal is usually to control the disease and improve quality of life with prolonged survival.
What symptoms does ovarian cancer cause in early stages?
In early stages it usually causes no clear symptoms. It may present with non-specific signs such as abdominal bloating, pelvic discomfort or subtle digestive changes that are easily mistaken for benign conditions. This lack of specific signs makes early detection difficult.
Is there an effective early detection test for ovarian cancer?
There is currently no universally effective screening method for the general population. Regular gynaecological follow-up and individual risk assessment (family history, BRCA1/BRCA2 mutations) help to detect it at earlier stages in higher-risk patients.
What factors influence survival in ovarian cancer?
The main factors are the tumour stage at diagnosis, the quality of the initial surgery (especially whether complete cytoreduction is achieved), tumour biology and histological subtype, the patient's genetic profile and the response to systemic treatment.
Why is it important to be treated in a specialised centre?
Because the team's experience and the volume of cases treated directly influence outcomes. Expert surgery and a multidisciplinary approach influence survival, especially in complex surgeries with peritoneal involvement.
What treatments are currently available for ovarian cancer?
Treatment includes oncological surgery with complete cytoreduction, systemic or intraperitoneal chemotherapy, targeted therapies (PARP inhibitors, anti-angiogenic agents such as bevacizumab) and, in selected cases, HIPEC. Molecular analysis allows treatment to be personalised according to the biological profile of the tumour.
What is the most important factor in ovarian cancer treatment?
One of the most decisive factors is achieving complete tumour resection at the initial surgery, since it is the modifiable prognostic factor with the greatest impact on survival. The quality of the first surgery shapes the entire subsequent course.
Is life expectancy the same for every patient with ovarian cancer?
No. It is understood as an individual outcome that depends on multiple clinical and biological factors and on the treatment approach. Two patients at the same stage can have very different prognoses depending on tumour biology, genetic profile and the centre where they are treated.
How has the prognosis of ovarian cancer changed in recent years?
Thanks to advances in cytoreductive surgery, targeted therapies (especially PARP inhibitors in BRCA-mutated patients) and molecular diagnosis, the approach has evolved towards personalised medicine that improves outcomes in many cases, particularly progression-free survival.
What sets an international reference centre apart in the treatment of ovarian cancer?
It brings together in a single multidisciplinary team oncological surgery, specialised medical oncology, molecular diagnostics and access to clinical trials, and the patient stays with that same team throughout treatment.